Dear Editor, Haemopoietic stem cell transplantation (HSCT) remains the only curative treatment for transfusion-dependent thalassaemia (TDT). Despite the curative intent, long-term complications like endocrinopathies can occur and cause significant morbidity. Previous studies have shown that 14.6-68% TDT post HSCT have gonadal dysfunction [1] [2] [3] [4] , 15-52% have short stature [1, 3] and 7-19% have hypothyroidism [1, [3] [4] [5] . Most previous studies describe the endocrinopathies but only two have compared with TDT [2, 4] . Most studies assessed iron overload by serum ferritin, which is not tissue-specific. MRI T2* is a more specific non-invasive measure to evaluate tissue iron in different organs [6] . With the availability of newer oral chelation, which have a high efficacy in iron chelation, better compliant and no negative impact on physical or sexual development in paediatric patients as compared to deferoxamine. We therefore took all these into consideration and carried out a study to evaluate the prevalence, cumulative incidence (CI) and risk factors of endocrinopathies of 40 TDT who underwent HSCT in 1992-2013, with ≥ 3 years of followup. We also randomly selected age-matched and sexmatched non-transplanted TDT controls for comparison. Demographics are summarised in Table 1. There were 23 patients who experienced acute GVHD (19 had skin GVHD, 8 had liver GVHD and 10 had gut GVHD) and 10 who experienced chronic GVHD. All required a brief period of steroid use, but were not dependent on steroid. The most prevalent endocrinopathy was gonadal dysfunction (55%), with a 5-year CI 30% and 10-year CI 55%, followed by growth failure and hypothyroidism (Fig. 1) . Younger age (≤ 7 years of age) at HSCT (adjusted OR 0.06, p = 0.018) and better Pesaro risk group (adjusted OR 0.04, p = 0.013) were protective factors for gonadal dysfunction. The mean height SD score (HtSDS) was significantly worse (p = 0.021) post transplantation (−0.84 ± 1.4). Transplant at an earlier age (≤ 8 years of age) was a protective factor for growth (adjusted OR 0.065, p = 0.045). Risk factors for hypothyroidism were higher post-transplant cardiac iron overload by MRI T2* (OR 82.6, p = 0.007). Twenty matched non-transplant controls were identified for a subset of posttransplant patients. Gonadal dysfunction appeared more prevalent in the transplant group (p = 0.001).
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The possible reasons for high-risk gonadal dysfunction post HSCT include the preexisting iron overload and the gonadotoxic conditioning regimen for the transplant. However, we could not demonstrate a significant association between the ferritin level and gonadal dysfunction. Hence, excess gonadal dysfunction in the HSCT group was likely due to HSCT itself, e.g., conditioning regimen. All patients who failed HSCT had gonadal dysfunction and this reflects the added toxicity of HSCT and iron overload. The conditioning regimens used were busulfan and cyclophosphamide. In females, alkylating agents are associated with premature ovarian failure. Ovarian recovery is sometimes observed. Interestingly, gonadal dysfunction does not preclude fertility. A female patient in our cohort with primary gonadal dysfunction post HSCT achieved motherhood by natural pregnancy twice. She was non-compliant with hormonal replacement therapy and achieved pregnancy and gave birth successfully. Repeated investigation after her first (10) 0.51
HLA-matched related donor transplant
Growth failure n (%) 10 (25%) 2 (40%) 0.6
Hypothyroidism n (%) 3 (7.5%) 2 (40%) 0.1
Abnormal glucose metabolism n (%) 5 (12.5%) 0 1
Adrenal insufficiency n (%) 3 (7.5%) 1 (20%) 0.39 delivery confirmed persistent elevation of the FSH and the status of primary gonadal dysfunction. De Sanctis et al. [2] also reported a post transplanted TDT patient became pregnant despite elevated gonadotropins and concluded that HSCT for thalassaemia does not preclude fertility at least in female. Hence biochemical gonadal dysfunction might not directly imply infertility. Further fertility assessment with anti-mullerian hormone, inhibin B, total antral follicle count and ovarian volume might be better assessment on the fertility potential in this group of patients. In males, infertility and persistent azoospermia after cytotoxic drugs is more common than hypogonadism as germ cells are more sensitive to alkylating agents. The mean busulfan dose in our HSCT group was 401.86 ± 644.75 mg/ m 2 and cyclophosphamide of 4.66 ± 1.09 g/m 2 . Busulfan levels were not measured in our study. Among all 9 males with gonadal dysfunction, 4 had isolated FSH elevation suggestive of seminiferous tubule dysfunction. Busulfan dose of 600 mg/m 2 [7] and cyclophosphasmide of 19 g/m 2 [8] are reported to cause prolonged azoospermia with a feedback rise in FSH. However, increased FSH does not equate azoospermia, and further investigation by semen analysis is needed. As the leydig cell function is usually not affected, there are normal testosterone production and secondary sexual characteristics. Growth retardation is almost invariably present in TDT. In our study, 25% of post-HSCT patients developed growth failure compared to 12.5% of growth failure before they underwent HSCT. There was also a significant decrease in HtSDS changes pre-and post HSCT. In contrast, in previous studies, HSCT was noted to have a positive effect on growth [9] . Our study result of better HtSDS pre-HSCT may be explained by better efficacy of chelation and lack of negative impact of bone dysplasia from deferoxamine. Short stature was less marked with HSCT at an earlier age, consistent with other studies [9] . This may be explained by less gonadal dysfunction in younger age at HSCT and hence less delayed sexual maturation.
In our study, 7.5% patients developed hypothyroidism after HSCT. In Savani et al., 12% of patients developed hypothyroidism and the average time to develop hypothyroidism is 4 years post HSCT [10] . We found that hypothyroidism was related to post-transplant cardiac iron overload measured by MRI T2*, in contrast to previous studies that showed that high ferritin level was related to higher chance of hypothyroidism [11] . There are several postulations. First, serum ferritin might not correlate well with tissue iron overload. Second, study showed that iron moves within tissue through a number of transporters. Voltage-dependent L-type calcium channels are divalent transporters that transport iron in heart tissue [12] . Extrinsic thyroid hormone increased L-type calcium channel mRNA expression and currents of ion channels in cardiac atrium and ventricles in animal studies [13, 14] . Hence, one of the postulation is that the increase in cardiac iron overload may be due to or worsened by patients with hypothyroidism taking extrinsic thyroxine. This also raises the question whether or not to treat subclinical hypothyroidism in TDT. Another possibility can be that the thyroid and the heart shared the same L-type calcium channel, and hence similar degree of iron overload. However, currently there is no evidence on this and hence more research should be carried out to explore the relationship on organ-specific iron overload and the thyroid function.
Previous studies reported limited number of diabetes mellitus or impaired glucose tolerance in post-HSCT TDT patients [3, 4] . We had two patients diagnosed with diabetes mellitus, one impaired fasting glucose and two patients impaired glucose tolerance post HSCT. It can be explained by different ways of screening and longer duration of follow-up. We also reported a positive correlation between the age of transplant and the risk of abnormal glucose metabolism, consistent with previous reports.
In a previous study, gonadal function is less prevalent in the HSCT group compared to the TDT group [4] . This finding was opposite to our findings. This can be explained by better chelation therapy nowadays so that the iron-related toxicity towards the gonads is decreased or reversed. Earlier HSCT reduced the risk of gonadal dysfunction, and hence HSCT is better performed at an earlier age to minimise gonadal dysfunction.
Transplant-related mortality is around 3% and morbidities include failed engraftment, acute to chronic GvHD, endocrinopathies, infertility and secondary malignancy, etc. However despite the risk, post transplanted thalassaemia patients enjoy better quality of life compared to TDT [15] . On the other hand, with better chelation, TDT cohort has improving survival and reducing complications. We should therefore thoroughly discuss all the pros and cons with the family before the decision of HSCT.
Current study has several limitations. First, the study design was retrospective and hence there were missing information and incomplete adjustment for confounding factors. Second, this is a single-centre study with a small number of patients, which may affect the statistical power. Third, a lot of data were excluded during age and sex matching because of unavailability of suitable controls. Hence, it may not be a full representation of the whole HSCT population. Fourth, MRI T2* was not available to assess iron overload in the past, and many patients did not have a pre-HSCT MRI T2*. Also, most MRI T2* assessment did not include endocrine organs. Therefore, we could not clearly correlate the iron deposition in endocrine glands with the function.
In conclusion, despite HSCT being the curative treatment of TDT, the occurrence of endocrine complications is not negligible. We demonstrated decrease in HtSDS post HSCT and a more prevalent gonadal dysfunction in the post-HSCT group. Age at HSCT is a major factor for the development of endocrinopathies. The family should be counselled about these morbidities before and after HSCT. Regular and long-term follow-up for endocrinopathies post HSCT is needed as complications such as gonadal dysfunction can occur years later and that it can be transient dysfunction and female patients may still be fertile intermittently. Further studies should be carried out for a better understanding of endocrinopathies, including hypoparathyroidism, osteopenia and fertility issues. And it is worthwhile to account for the duration of transplant when comparing to controls (when study population is sufficient) and to compare the incidence of endocrinopathies after HSCT in thalassaemia patients with that in nonthalassaemia HSCT patients.
